{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:26:41Z","timestamp":1792207601635,"version":"4.4.0"},"reference-count":52,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious prothrombotic adverse event after vaccination with adenovector-based COVID-19 vaccines. Laboratory findings indicate that anti\u2013platelet factor 4 (PF4) immunoglobulin G antibodies are the causing factor for the onset of thromboembolic events in VITT. However, molecular mechanisms of cellular interactions, signaling pathways and involvement of different cell types in VITT antibody\u2013mediated thrombosis are not fully understood. Moreover, uncertainty exists regarding current treatment protocols because the sole anticoagulation was shown to be inefficient to prevent thrombosis progression in severe VITT cases. In this study, we demonstrate that platelet spleen tyrosine kinase (SYK) modulates anti-PF4 VITT-mediated thrombus formation in an ex\u00a0vivo model of immunothrombosis. Our study\u00a0showed that the selective inhibition of SYK can abrogate VITT antibody\u2013driven procoagulant platelet formation, activation of plasmatic coagulation as well as platelet-leukocyte interplay. Most importantly, the specific inhibition of SYK in platelets but not in neutrophils prevented VITT antibody\u2013induced multicellular thrombus formation, without perturbing the platelet function. Our findings indicate that the specific targeting of platelet SYK might be a promising therapeutic approach to prevent thrombotic complications in patients with antibody-mediated immunothrombosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014167","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T19:59:28Z","timestamp":1734724768000},"page":"1772-1785","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Platelet spleen tyrosine kinase is a key regulator of anti-PF4 antibody\u2013induced immunothrombosis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8245-8064","authenticated-orcid":false,"given":"Jan","family":"Zlamal","sequence":"first","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"},{"name":"2Centre for Clinical Transfusion Medicine, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera M.","family":"Ripoll","sequence":"additional","affiliation":[{"name":"3ANZAC Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"4Department of Haematology, Concord Repatriation General Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia"},{"name":"5Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-9364","authenticated-orcid":false,"given":"Christine S.M.","family":"Lee","sequence":"additional","affiliation":[{"name":"3ANZAC Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"4Department of Haematology, Concord Repatriation General Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia"},{"name":"5Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia"},{"name":"6Division of Genome Science and Cancer, John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Toma","sequence":"additional","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Althaus","sequence":"additional","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"},{"name":"2Centre for Clinical Transfusion Medicine, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavianna","family":"Rigoni","sequence":"additional","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"},{"name":"2Centre for Clinical Transfusion Medicine, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Witzemann","sequence":"additional","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Whittaker","sequence":"additional","affiliation":[{"name":"3ANZAC Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"4Department of Haematology, Concord Repatriation General Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia"},{"name":"5Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Capraro","sequence":"additional","affiliation":[{"name":"3ANZAC Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-6230","authenticated-orcid":false,"given":"G\u00fcnalp","family":"Uzun","sequence":"additional","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"},{"name":"2Centre for Clinical Transfusion Medicine, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-6812","authenticated-orcid":false,"given":"Tamam","family":"Bakchoul","sequence":"additional","affiliation":[{"name":"1Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany"},{"name":"2Centre for Clinical Transfusion Medicine, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5119-7470","authenticated-orcid":false,"given":"Vivien M.","family":"Chen","sequence":"additional","affiliation":[{"name":"3ANZAC Research Institute, Sydney Local Health District, Sydney, New South Wales, Australia"},{"name":"4Department of Haematology, Concord Repatriation General Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia"},{"name":"5Concord Clinical School, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"12","key":"2025042208420210600_bib1","first-page":"CD015477","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Grana","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"2025042208420210600_bib2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2025042208420210600_bib3","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2025042208420210600_bib4","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2025042208420210600_bib5","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/blood.2022016474","article-title":"Vaccine-induced immune thrombotic thrombocytopenia is mediated by a stereotyped clonotypic antibody","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025042208420210600_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.2023021307","article-title":"Characterization of reverse-engineered anti-PF4 stereotypic antibodies derived from serum of patients with VITT","volume":"143","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"7873","key":"2025042208420210600_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature"},{"issue":"4","key":"2025042208420210600_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood.2021012152","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know","volume":"138","author":"Arepally","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2025042208420210600_bib9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0043-1761269","article-title":"Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia","volume":"49","author":"Selvadurai","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2025042208420210600_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12185-022-03516-4","article-title":"Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder","volume":"117","author":"Venier","year":"2023","journal-title":"Int J Hematol"},{"issue":"11","key":"2025042208420210600_bib11","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/bloodadvances.2021006698","article-title":"A\u00a0novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"6","author":"Lee","year":"2022","journal-title":"Blood Adv"},{"key":"2025042208420210600_bib12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-0716-3175-1_29","article-title":"Whole blood procoagulant platelet flow cytometry protocol for heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic thrombocytopenia (VITT) testing","volume":"2663","author":"Lee","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"8","key":"2025042208420210600_bib13","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3324\/haematol.2021.279000","article-title":"Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia","volume":"106","author":"Althaus","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2025042208420210600_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/bloodadvances.2021005210","article-title":"Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19","volume":"6","author":"Zlamal","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2025042208420210600_bib15","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2010-03-274969","article-title":"PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model","volume":"117","author":"Reilly","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2025042208420210600_bib16","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.3324\/haematol.2022.282275","article-title":"Platelet phosphatidylserine is the critical mediator of thrombosis in heparin-induced thrombocytopenia","volume":"108","author":"Zlamal","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2025042208420210600_bib17","first-page":"2010","article-title":"Cerebral venous sinus thrombosis and thrombocytopenia due to heparin-independent anti-PF4 antibodies after adenovirus infection","volume":"109","author":"Uzun","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"2025042208420210600_bib18","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: a multicenter study comprising 1284 patients","volume":"20","author":"Favaloro","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2025042208420210600_bib19","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood-2011-07-367334","article-title":"Human Fc\u03b3RIIA induces anaphylactic and allergic reactions","volume":"119","author":"Jonsson","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2025042208420210600_bib20","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/blood-2015-04-638684","article-title":"CD32a antibodies induce thrombocytopenia and type II hypersensitivity reactions in FCGR2A mice","volume":"126","author":"Meyer","year":"2015","journal-title":"Blood"},{"issue":"Pt 2","key":"2025042208420210600_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/bj3110471","article-title":"Syk interacts with tyrosine-phosphorylated proteins in human platelets activated by collagen and cross-linking of the Fc gamma-IIA receptor","volume":"311","author":"Yanaga","year":"1995","journal-title":"Biochem J"},{"issue":"51","key":"2025042208420210600_bib22","doi-asserted-by":"crossref","first-page":"32435","DOI":"10.1016\/S0021-9258(18)31653-3","article-title":"Clustering of the platelet Fc gamma receptor induces noncovalent association with the tyrosine kinase p72syk","volume":"269","author":"Chacko","year":"1994","journal-title":"J\u00a0Biol Chem"},{"issue":"39","key":"2025042208420210600_bib23","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1093\/eurheartj\/ehab506","article-title":"Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia","volume":"42","author":"Holm","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"2025042208420210600_bib24","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-022-32946-1","article-title":"NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Leung","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"2025042208420210600_bib25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/ana.26431","article-title":"Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination","volume":"92","author":"Scutelnic","year":"2022","journal-title":"Ann Neurol"},{"issue":"8","key":"2025042208420210600_bib26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025042208420210600_bib27","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.2021012479","article-title":"The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Uzun","year":"2021","journal-title":"Blood"},{"issue":"23","key":"2025042208420210600_bib28","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1182\/blood.2021013839","article-title":"The interaction between anti-PF4 antibodies and anticoagulants in vaccine-induced thrombotic thrombocytopenia","volume":"139","author":"Singh","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025042208420210600_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2025042208420210600_bib30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jmb.2012.11.007","article-title":"Structural and biophysical characterization of the Syk activation switch","volume":"425","author":"Gradler","year":"2013","journal-title":"J\u00a0Mol Biol"},{"issue":"14","key":"2025042208420210600_bib31","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025042208420210600_bib32","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2025042208420210600_bib33","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025042208420210600_bib34","unstructured":"Kronos Bio\n          . A study to evaluate Lanraplenib (LANRA) in combination with Gilteritinib in participants with FLT3-mutated relapsed or refractory acute myeloid leukemia (AML). ClinicalTrials.gov identifier: NCT05028751. Updated 7 August 2024. Accessed 18 April 2024. https:\/\/clinicaltrials.gov\/study\/NCT05028751?term=NCT05028751&rank=1."},{"issue":"25","key":"2025042208420210600_bib35","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2021012277","article-title":"Antiplatelet drugs block platelet activation by VITT patient serum","volume":"138","author":"Smith","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025042208420210600_bib36","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1111\/j.1538-7836.2011.04470.x","article-title":"The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies","volume":"9","author":"Lhermusier","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2025042208420210600_bib37","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1538-7836.2009.03451.x","article-title":"The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets","volume":"7","author":"Spalton","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"2025042208420210600_bib38","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1111\/jth.15098","article-title":"Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in\u00a0vitro and in\u00a0vivo","volume":"18","author":"Series","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2025042208420210600_bib39","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.2023020872","article-title":"PF4 activates the c-Mpl-Jak2 pathway in platelets","volume":"143","author":"Buka","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2025042208420210600_bib40","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3324\/haematol.2021.280251","article-title":"The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies","volume":"107","author":"Vayne","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"2025042208420210600_bib41","doi-asserted-by":"crossref","first-page":"e396","DOI":"10.1161\/ATVBAHA.123.319522","article-title":"PAD4-induced NETosis via cathepsin G-mediated platelet-neutrophil interaction in ChAdOx1 vaccine-induced thrombosis-brief report","volume":"43","author":"Carnevale","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2025042208420210600_bib42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood.V75.3.550.550","article-title":"GMP-140 mediates adhesion of stimulated platelets to neutrophils","volume":"75","author":"Hamburger","year":"1990","journal-title":"Blood"},{"issue":"4","key":"2025042208420210600_bib43","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI118234","article-title":"Neutrophils use both shared and distinct mechanisms to adhere to selectins under static and flow conditions","volume":"96","author":"Patel","year":"1995","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2025042208420210600_bib44","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.2019002124","article-title":"Platelet necrosis mediates ischemic stroke outcome in mice","volume":"135","author":"Denorme","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2025042208420210600_bib45","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1182\/blood.V98.4.1252","article-title":"Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8","volume":"98","author":"Arepally","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2025042208420210600_bib46","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI60229","article-title":"New insights into the mechanisms of venous thrombosis","volume":"122","author":"Mackman","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"2025042208420210600_bib47","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2025042208420210600_bib48","doi-asserted-by":"crossref","first-page":"e200127","DOI":"10.1212\/NXI.0000000000200127","article-title":"Immunohistologic features of cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia","volume":"10","author":"Geeraerts","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10306","key":"2025042208420210600_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","article-title":"Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study","volume":"398","author":"Perry","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"2025042208420210600_bib50","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025042208420210600_bib51","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"2025042208420210600_bib52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2024024250","article-title":"Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice","volume":"144","author":"Gonzalez-Lopez","year":"2024","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1772\/2367630\/blooda_adv-2024-014167-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1772\/2367630\/blooda_adv-2024-014167-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:42:14Z","timestamp":1745325734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1772\/534791\/Platelet-spleen-tyrosine-kinase-is-a-key-regulator"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014167","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}